Austin Angelo

About the Author Austin Angelo


Stephens Maintains Their Buy Rating on Independent Bank Group (IBTX)

Stephens analyst Matt Olney maintained a Buy rating on Independent Bank Group (IBTX) today and set a price target of $67. The company’s …

Analysts Are Bullish on Top Healthcare Stocks: T2 Biosystems (TTOO), Evolus Inc (EOLS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on T2 Biosystems (TTOO) and Evolus …

Shoe Carnival (SCVL) Gets a Buy Rating from Pivotal Research

Pivotal Research analyst Mitch Kummetz reiterated a Buy rating on Shoe Carnival (SCVL) today and set a price target of $38. The company’s …

BMO Capital Reaffirms Their Buy Rating on Linde plc (LIN)

BMO Capital analyst John McNulty maintained a Buy rating on Linde plc (LIN) today and set a price target of $210. The company’s …

Northland Securities Reaffirms Their Hold Rating on Medtronic (MDT)

Northland Securities analyst Suraj Kalia maintained a Hold rating on Medtronic (MDT) today and set a price target of $84. The company’s shares …

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI), Autolus Therapeutics Plc (AUTL) and Trillium Therapeutics (TRIL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics (KPTI), Autolus Therapeutics …

Analysts Are Neutral on These Services Stocks: Best Buy Co (BBY), JC Penney (JCP)

Analysts fell to the sidelines weighing in on Best Buy Co (BBY) and JC Penney (JCP) with neutral ratings, indicating that the experts …

Spectra7 Microsys (SEV) Receives a Sell from Canaccord Genuity

In a new note to investors yesterday, an analyst has provided a rating update for the Consumer Goods sector company, Spectra7 Microsys (SEV). …

NeoPhotonics (NPTN) Received its Third Buy in a Row

After MKM Partners and Northland Securities gave NeoPhotonics (NYSE: NPTN) a Buy rating last month, the company received another Buy, this time from …

Chardan Capital Reiterates a Buy Rating on OncoCyte Corp (OCX)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on OncoCyte Corp (OCX), with a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts